Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.61 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | CHEK1 | O14757 | 7/20 | 0.47 |
| ▸ | WEE1 | P30291 | 6/20 | 0.47 |
| ▸ | CDK1 | P06493 | 1/20 | 0.45 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.45 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.44 |
| ▸ | MTOR | P42345 | 1/20 | 0.44 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6495062 | 0.81 | WEE1 (0.50) | TDP1ESR1CHEK1WEE1PIK3CA | |
| SCHEMBL6504264 | 0.79 | PTGDR2 (0.41) | TDP1CHEK1WEE1 | |
| SCHEMBL6503691 | 0.78 | TDP1 (0.40) | TDP1CHEK1WEE1 | |
| SCHEMBL6505751 | 0.78 | PTGDR2 (0.41) | TDP1CHEK1WEE1 | |
| SCHEMBL6505761 | 0.78 | PTGDR2 (0.41) | TDP1CHEK1WEE1 | |
| SCHEMBL6505681 | 0.78 | NTRK1 (0.43) | TDP1CHEK1WEE1 | |
| SCHEMBL6505755 | 0.77 | TDP1 (0.40) | TDP1ESR1CHEK1WEE1MAPK1 | |
| SCHEMBL16710312 | 0.76 | TDP1 (1.00) | TDP1MAPK1 | |
| SCHEMBL18326676 | 0.72 | TDP1 (0.90) | TDP1PIK3CAMTORPIK3CGMAPK1 | |
| SCHEMBL18319822 | 0.72 | TDP1 (0.80) | TDP1CHEK1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1245565-B1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | SERVIER LAB (FR) | 2003-09-24 | — | — | EP | claimed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | claimed |
| EP-1245565-A1 | Indenoindolone derivatives, process for their preparation and pharmaceutical compositions containing them | Les Laboratoires Servier (FR) | 2002-10-02 | — | — | EP | claimed |
| US-6844445-B2 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2005-01-18 | — | — | US | disclosed |
| US-20020173531-A1 | Indenoindolone compounds | LES LABORATOIRES SERVIER (FR) | 2002-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020173531-A1 | Indenoindolone compounds | MTNR1A, MTNR1B, CYP11B1 | TDP1 2566/4885ESR1 973/4885CHEK1 4552/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.